At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 69 enrolled
Drug / intervention
Lemborexant 5 mg +3 moredrug
Likely dose
Lemborexant 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder
In Brief
A Phase 1 clinical trial evaluating Lemborexant 5 mg, Lemborexant 10 mg, and 2 other interventions for Insomnia Disorder. Completed, enrolled 69 participants across 2 sites.
Detailed Summary
This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of lemborexant (5 mg and 10 mg) in participants with insomnia disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsomnia Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedJan 2015
Primary CompletionApr 2015
TodayJul 2026
First PostedJan 29, 2015
Enrollment StartDec 13, 2014
Primary CompletionApr 21, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.4 years ago
Interventions
Lemborexant 5 mgdrug
Lemborexant 5 mg tablet.
Lemborexant 10 mgdrug
Lemborexant 10 mg tablet.
Lemborexant-matched placebo.drug
Lemborexant-matched placebo tablet.
Flurazepam 30 mgdrug
Flurazepam 30 mg capsule.